ANXA5 and breast cancer: The dose–response relationships for free ANTR drugs and APO-encapsulated ANTR nanodrugs have been evaluated based on the flow cytometry data obtained for MDA-MB-231 breast cancer cells treated with these drugs and analyzed by the annexin V and 7-ADD staining.